cascade and has received great interest as a potential target for the development of new antithrombotic agents. Most of amidine-type FXa inhibitors reported have been found to show extremely poor oral bioavailability. Compound 1 is one of the first reported non-amidine type FXa inhibitors. To discover novel and orally active FXa inhibitors, we investigated flexible linear linkers between the 6-chloronaphthalene
Xa因子(FXa)是一种参与凝血级联反应的胰
蛋白酶样
丝氨酸蛋白酶,作为开发新型抗血栓药的潜在靶标已引起广泛关注。已发现大多数报道的am型FXa
抑制剂显示出极差的口服
生物利用度。化合物1是最早报道的非-型FXa
抑制剂之一。为了发现新颖的口服活性FXa
抑制剂,我们研究了6-
氯萘环与1的1-(
吡啶-4-基)
哌啶部分之间的柔性线性接头,发现口服活性的磺酰基烷基
酰胺2f与FXa IC(50)相同。 0.05 microM,与1相当。进一步的修饰以降低2f的CYP3A4抑制活性导致产生有力,选择性和口服活性的2-
甲基吡啶类似物2s(FXa IC(50)为0.061 microM),CYP3A4抑制作用比2f显着减弱。化合物2s在食蟹猴中也显示出持久的抗凝活性。